Breast Cancer Trial, Recruiting NCT07512271 Sponsor: University of California, San Francisco Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07512271
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 or older, of any gender.
  • People who have either: Stage IV breast cancer where their treatment is changing and they are expected to have check-up visits at least once every three months, OR Stage I–III breast cancer that was diagnosed within the last 6 months.
  • People who have basic computer skills and regular access to the internet at home.
  • People who are able to understand what the study involves and follow the study procedures for its full duration.
  • People, or their legal guardian or representative, who are able to understand and are willing to sign a written consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People for whom any study-related procedure or assessment is medically unsuitable (confirm with trial site).
  • People whose thinking or memory difficulties would make it hard to use the study tools or complete surveys.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michelle Melisko, MD, University of California, San Francisco

Phone: 877-827-3222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean score of Safety and Risk Assessment (Lead-in and Provider); Mean score of Provider Assessment of AI patient Education Tool Survey (Provider); Mean score of Assessment of Answer Accuracy and Content Appropriateness (Provider)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov